OUR TESTS

The molecular profile to define and defeat her unique cancer.


Will my patient’s breast cancer return after surgery?

The MammaPrint® test analyzes the 70 most important genes associated with breast cancer recurrence. Results are typically available in 6 days or less, MammaPrint enables quicker, more informed decisions on pre- and post-operative treatment and can easily be integrated into diagnostic workups.

ORDER A TEST >

I see MammaPrint as a great tool which helps you to navigate through difficult decisions.’

— Andrea, a breast cancer survivor

Women who benefit.

Definitive results for adjuvant chemotherapy planning.

LOW RISK PATIENTS HAVE A

1.3%

CHANCE OF RECURRENCE 2

The MINDACT trial determined these patients do not benefit from chemotherapy.3

HIGH RISK PATIENTS HAVE A

11.7%

CHANCE OF RECURRENCE 2

These patients were shown to have significantly better outcomes with chemotherapy.4

46%

Nearly half of clinically high risk patients were reclassified as MammaPrint Low Risk and were able to forgo chemotherapy without compromising their outcomes.3

OUR PROOF

Implemented across the entire medical community.

Supported by
Data

The validity and utility of
MammaPrint is supported by numerous
peer-reviewed publications.

Recommended
by Leading Authorities
Chosen by
Physicians

Healthcare professionals reported higher confidence in their treatment recommendations after receiving a MammaPrint result.

Requested by
Patients

Having learned the unique benefits of
genomic testing in recent years, thousands
of patients globally have requested MammaPrint.

THE MAMMAPRINT + BLUEPRINT TEST SUITE
Analyze over a hundred relevant genes at once.

With the additional results of BluePrint, our molecular subtyping test, physicians gain an even broader genomic profile. From just one tumor block, you can interrogate over 150 genes containing information on a tumor’s level of aggression and potential for growth. These insights will serve as an essential resource for guiding your pre- and post-operative treatment strategies.

BLUEPRINT
1. Following the 2016 Publication of MINDACT, the 2017 ASCO guidelines were updated to indicate favorable results in patients with 1-3 positive lymph nodes. MammaPrint’s 510(k) FDA clearance includes breast cancer patients with Stage 1 or Stage II disease, with tumor size ≤ 5.0 cm and lymph node negative.
2. FDA 510(k) clearance (K201902)
3. Cardoso, F., et al. N Engl J Med 2016;375:717-29.
4. Knauer, M., et al. Breast Cancer Res Treat. 2010 Apr;120(3):655-61.